Get the Stockscreener App
441.30
1.04%
4.56
After Hours:
441.30
Intuitive Surgical Inc stock is traded at $441.30, with a volume of 1.17M.
It is up +1.04% in the last 24 hours and down -0.28% over the past month.
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 8,600 da Vinci systems in hospitals worldwide, with more than 5,000 installations in the US and a growing number in emerging markets.
See More
Previous Close:
$436.74
Open:
$438.6
24h Volume:
1.17M
Market Cap:
$156.82B
Revenue:
$7.57B
Net Income/Loss:
$2.09B
P/E Ratio:
103.84
EPS:
4.25
Net Cash Flow:
$419.50M
1W Performance:
-3.01%
1M Performance:
-0.28%
6M Performance:
+17.76%
1Y Performance:
+33.98%
1D Range:
$432.87
$446.16
52W Range:
$254.85
$468.78
Intuitive Surgical Inc Stock (ISRG) Company Profile
Name
Intuitive Surgical Inc
Sector
Industry
Phone
(408) 523-2100
Address
1020 KIFER ROAD, SUNNYVALE
Intuitive Surgical Inc Stock (ISRG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-17-23 | Initiated | HSBC Securities | Buy |
| Jul-19-23 | Initiated | Robert W. Baird | Outperform |
| Apr-19-23 | Reiterated | BTIG Research | Buy |
| Apr-19-23 | Reiterated | BofA Securities | Buy |
| Apr-19-23 | Reiterated | Citigroup | Buy |
| Apr-19-23 | Reiterated | Evercore ISI | In-line |
| Apr-19-23 | Reiterated | JP Morgan | Overweight |
| Apr-19-23 | Reiterated | Morgan Stanley | Equal-Weight |
| Apr-19-23 | Reiterated | RBC Capital Mkts | Outperform |
| Apr-19-23 | Reiterated | Raymond James | Outperform |
| Apr-19-23 | Reiterated | Stifel | Buy |
| Apr-19-23 | Reiterated | Truist | Buy |
| Apr-19-23 | Reiterated | Wells Fargo | Overweight |
| Mar-29-23 | Initiated | UBS | Neutral |
| Mar-23-23 | Initiated | William Blair | Outperform |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-13-22 | Initiated | Mizuho | Neutral |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Apr-13-22 | Initiated | Truist | Buy |
| Apr-06-22 | Initiated | Wolfe Research | Peer Perform |
| Mar-25-22 | Initiated | RBC Capital Mkts | Outperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Feb-02-22 | Upgrade | UBS | Neutral → Buy |
| Jan-31-22 | Upgrade | Piper Sandler | Neutral → Overweight |
| Jan-25-22 | Downgrade | Redburn | Buy → Neutral |
| Jan-21-22 | Reiterated | BTIG Research | Buy |
| Jan-21-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-21-22 | Reiterated | Deutsche Bank | Hold |
| Jan-21-22 | Reiterated | Evercore ISI | In-line |
| Jan-21-22 | Reiterated | Morgan Stanley | Equal-Weight |
| Jan-21-22 | Reiterated | Piper Sandler | Neutral |
| Jan-21-22 | Reiterated | Raymond James | Outperform |
| Jan-21-22 | Reiterated | Robert W. Baird | Outperform |
| Jan-21-22 | Reiterated | Stifel | Buy |
| Jan-21-22 | Reiterated | UBS | Neutral |
| Jan-21-22 | Reiterated | Wells Fargo | Overweight |
| Jan-10-22 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-01-21 | Downgrade | Citigroup | Buy → Neutral |
| Jul-21-21 | Reiterated | BofA Securities | Neutral |
| Jul-21-21 | Reiterated | Citigroup | Buy |
| Jul-21-21 | Reiterated | JP Morgan | Overweight |
| Jul-21-21 | Reiterated | Morgan Stanley | Equal-Weight |
| Jul-21-21 | Reiterated | Piper Sandler | Neutral |
| Jul-21-21 | Reiterated | SVB Leerink | Mkt Perform |
| Jul-21-21 | Reiterated | Stifel | Buy |
| Jul-21-21 | Reiterated | UBS | Neutral |
| Jul-21-21 | Reiterated | Wells Fargo | Overweight |
| Jul-14-21 | Reiterated | Goldman | Buy |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Apr-21-21 | Upgrade | Oppenheimer | Underperform → Perform |
| Apr-21-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-01-21 | Initiated | Citigroup | Buy |
| Dec-15-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-28-20 | Initiated | Argus | Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Sep-08-20 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-02-20 | Initiated | Robert W. Baird | Neutral |
| Jul-20-20 | Reiterated | Bernstein | Outperform |
| Apr-28-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Apr-17-20 | Downgrade | CFRA | Hold → Sell |
| Apr-17-20 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Apr-09-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Apr-01-20 | Downgrade | Oppenheimer | Perform → Underperform |
| Jan-27-20 | Downgrade | Deutsche Bank | Buy → Hold |
| Dec-12-19 | Reiterated | Wells Fargo | Outperform |
| Nov-21-19 | Initiated | Oppenheimer | Perform |
| Jul-19-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-22-19 | Reiterated | Canaccord Genuity | Buy |
| Apr-02-19 | Initiated | Deutsche Bank | Buy |
| Oct-31-18 | Reiterated | Piper Jaffray | Overweight |
| Oct-19-18 | Upgrade | Canaccord Genuity | Hold → Buy |
View All
Intuitive Surgical Inc Stock (ISRG) Latest News
Intuitive Surgical Inc. stock rises Friday, still underperforms market - MarketWatch
MarketWatch
There May Be Underlying Issues With The Quality Of Intuitive Surgical's (NASDAQ:ISRG) Earnings - Simply Wall St
Simply Wall St
ISRG: 3 Leading Stocks in the Robotics Industry - StockNews.com
StockNews.com
Brokers Suggest Investing in Intuitive Surgical (ISRG): Read This Before Placing a Bet - Zacks Investment Research
Zacks Investment Research
Brokers Suggest Investing in Intuitive Surgical (ISRG): Read This Before Placing a Bet - Yahoo Canada Finance
Yahoo Canada Finance
Better Buy: Abbott Laboratories vs. Intuitive Surgical - MSN
MSN
Intuitive Surgical Inc Stock (ISRG) Financials Data
Revenue
Net Income
Cash Flow
EPS
Intuitive Surgical Inc Stock (ISRG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Curet Myriam | EVP & Chief Medical Officer |
Jul 23 '24 |
Option Exercise |
177.99 |
2,818 |
501,567 |
3,116 |
| BARRATT CRAIG H | Director |
Jul 23 '24 |
Option Exercise |
56.97 |
1,400 |
79,764 |
1,400 |
| Curet Myriam | EVP & Chief Medical Officer |
Jul 23 '24 |
Sale |
458.13 |
2,818 |
1,291,010 |
298 |
| BARRATT CRAIG H | Director |
Jul 23 '24 |
Sale |
458.13 |
1,400 |
641,382 |
0 |
| BARRATT CRAIG H | Director |
Jun 12 '24 |
Option Exercise |
56.97 |
1,400 |
79,764 |
1,400 |
| BARRATT CRAIG H | Director |
Jun 12 '24 |
Sale |
421.06 |
1,400 |
589,484 |
0 |
| DeSantis Robert | EVP & Chief Strategy & Corp Op |
Jun 10 '24 |
Option Exercise |
266.87 |
239 |
63,783 |
5,626 |
| Rosa David J. | President |
Jun 10 '24 |
Option Exercise |
0.00 |
1,359 |
0 |
216,644 |
| DeSantis Robert | EVP & Chief Strategy & Corp Op |
Jun 10 '24 |
Sale |
416.60 |
239 |
99,567 |
5,506 |
| BARRATT CRAIG H | Director |
Jun 05 '24 |
Option Exercise |
56.97 |
1,400 |
79,764 |
1,400 |
1.94%
5.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):